| "Hjälper kvinnor att följa sin ägglossning på ett smartare sätt" | 
Key takeaways
- Polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) is associated with several long-term health considerations, which is part of why the name now includes ”metabolic”.
- The 2023 International Evidence-Based Guideline recommends that clinicians address metabolic, cardiovascular, sleep and psychological features once a diagnosis is made.
- An association is not a prediction. It describes a group, not an individual.
- The guideline recognises an increased premenopausal risk of endometrial cancer while noting that absolute risks remain low (DOI: 10.1210/clinem/dgad463).
- What monitoring is appropriate for you is a clinical decision, not something to work out from an article.
The 2023 International Evidence-Based Guideline recommends that once PMOS is diagnosed, assessment and management address reproductive, metabolic, cardiovascular, dermatologic, sleep and psychological features. These are associations observed across groups of people, not predictions about any individual, and what monitoring is appropriate is a decision for a clinician who knows your full picture.
Why does long-term health come up at all?
Because the condition involves more than cycles, which is what the renaming was meant to communicate.
The 2023 International Evidence-Based Guideline recommends that once a diagnosis is made, assessment and management address reproductive, metabolic, cardiovascular, dermatologic, sleep and psychological features (DOI: 10.1210/clinem/dgad463).1 It also recommends a lifelong reproductive health plan.1
Reproductive · Metabolic · Cardiovascular · Dermatologic · Sleep · Psychological
That breadth is the point. Historically the condition was framed around fertility and cycles, and the rest received less attention. The guidance now treats the wider picture as part of routine care rather than as a complication to deal with later.
What does the guideline actually say?
Its recommendations are written for healthcare professionals. Here is what they cover, in plain terms (DOI: 10.1210/clinem/dgad463).1
| Area | What the 2023 guideline says (DOI: 10.1210/clinem/dgad463) |
|---|---|
| Metabolic and diabetes | Metabolic risk factors and diabetes are increased; screening and management are recommended |
| Cardiovascular | Cardiovascular disease risk is increased; screening and management are recommended |
| Sleep | Sleep disorders are increased; screening and management are recommended |
| Psychological | Depressive and anxiety symptoms are significantly increased and should be screened for in all patients |
| Pregnancy | PMOS should be considered a high-risk condition in pregnancy, with monitoring |
| Endometrial cancer | An increased premenopausal risk should be recognised, while absolute risks remain low |
Two things about that table are worth saying out loud.
The last row is the one people find most alarming, and the guideline’s own framing includes the qualifier: the risk is increased, and the absolute risk remains low (DOI: 10.1210/clinem/dgad463).1 Both halves are part of the recommendation. Reporting only the first half would misrepresent it.
And ”screening is recommended” is guidance to clinicians about what to consider. It is not a schedule for you to follow, and this article deliberately does not contain one.
What an association actually means
This is the part that decides whether the rest of the article is useful or frightening.
An association describes a pattern across a group. It says that, on average, a particular outcome is observed more often among people with the condition than among people without it. It does not say the outcome will happen to any given person, and it does not say it is happening to you now.
Three things follow from how the guideline frames these associations (DOI: 10.1210/clinem/dgad463):
- Increased risk is not high risk. A risk can be meaningfully increased relative to a baseline and still be small in absolute terms, which is the case in the endometrial cancer row above.
- These are group findings. Individual risk depends on many things a group statistic does not capture.
- Knowing about an association is what makes it actionable. The reason the guideline lists these is so clinicians look at them, which is only useful if they are looked at.
Why psychological features are on the list
Because the evidence supports it, and because it is the part most often left out.
The guideline is direct: depressive and anxiety symptoms are significantly increased and should be screened for in all people with the condition, with assessment and therapy where indicated.1 It also calls for greater awareness of psychological features including eating disorders and the impact on body image and quality of life.1
This is a clinical recommendation, not a footnote. If you have the condition and nobody has ever asked how you are doing, that is a gap in your care rather than a topic that does not apply.
What you can reasonably ask
Since screening intervals and specific tests depend on your situation, the useful move is to ask rather than to work it out:
- Given my diagnosis, what should we be keeping an eye on over time?
- Is there anything you would want to check now, and anything on a longer cycle?
- What would change your answer to that?
- Who should I be seeing, and how often?
These are ordinary questions. Asking them is not asking for special treatment.
What this means for tracking with Premom
Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.
Nothing in this article is visible in a tracking app. Metabolic, cardiovascular and psychological assessment all happen in a clinical setting, with tests and conversations an app has no access to.
A record of cycle dates over months contributes to one part of the picture and is easier to bring to an appointment than to recall. That is its role here, and it is a small one.
When to talk to a clinician
The information here is general and is not a basis for self-diagnosis or for changing anything about your health on your own. Speak with a clinician if:
- You have a PMOS diagnosis and long-term health hasn’t been discussed with you yet
- You are worried about a specific risk after reading about it, including here
- You have symptoms of low mood or anxiety, whether or not they seem connected
- You are pregnant or planning a pregnancy, since the guideline treats this as a high-risk condition in pregnancy1
If reading this has made you anxious, that is a reasonable thing to say to a clinician too. It is useful information for them.
Frequently asked questions
No. The guideline notes that metabolic risk factors and diabetes are increased and recommends screening (DOI: 10.1210/clinem/dgad463). That describes a pattern across a group. It is not a prediction about any individual.
The guideline recognises an increased premenopausal risk of endometrial cancer while noting that absolute risks remain low (DOI: 10.1210/clinem/dgad463). Both halves are part of the recommendation. A risk can be meaningfully increased and still be small in absolute terms.
That an outcome is observed more often, on average, among people with the condition than among people without it. It does not say the outcome will happen to you, and individual risk depends on much that a group statistic does not capture.
That depends on your situation and belongs with a clinician. A useful question to ask is what should be kept an eye on over time, what is worth checking now, and what would change the answer.
Because the guideline is direct about it: depressive and anxiety symptoms are significantly increased and should be screened for in all patients (DOI: 10.1210/clinem/dgad463). If nobody has asked how you are doing, that is a gap in care rather than a topic that does not apply.
About PMOS
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.2 A three-year transition runs to 2028, and both names remain in clinical use. Diagnostic criteria did not change, and an existing PCOS diagnosis remains valid.
In adults, diagnosis requires two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone, after other causes are excluded.1 Reported prevalence varies with the criteria applied; the guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).1
References
- Teede HJ, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463 · PMID 37580314.
- Teede HJ, et al. The Lancet, 12 May 2026. DOI 10.1016/S0140-6736(26)00717-8 · PMID 42119588.
